Currently out of the existing stock ratings of Yigal Nochomovitz, 94 are a HOLD (15.26%), 503 are a BUY (81.66%), 19 are a SELL (3.08%).

Yigal Nochomovitz

Work Performance Price Targets & Ratings Chart

Analyst Yigal Nochomovitz, currently employed at CITI, carries an average stock price target met ratio of 47.24% that have a potential upside of 57.9% achieved within 270 days. Previously, Yigal Nochomovitz worked at OPPENHEIMER.

Yigal Nochomovitz’s has documented 1,160 price targets and ratings displayed on 70 stocks. The coverage is on Healthcare, Industrials, Consumer Cyclical sectors.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 29-Jun-2026.

Wall Street Analyst Yigal Nochomovitz

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 3/16/2020. The price target of $2.3 was fulfilled within 1 day with a profit of $0.25 (12.2%) receiving and performance score of 121.95.

Average potential price target upside

of $364.25 (39.99%) on ATRA (ATARA BIOTHERAPEUTICS).
of $66.93 (115.89%) on RETA (REATA PHARMACEUTICALS).
of $66.6 (97.39%) on ARAV (ARAVIVE).

AERI Aerie Pharmaceuticals ALDX Aldeyra The APLS Apellis Pharmaceuticals ARCT Arcturus Therapeutics Holdings ARDX Ardelyx ARVN Arvinas ATRA Atara Biotherapeutics CLLS Cellectis SA CRBU Caribou Biosciences CRSP Crispr Therapeutics AG DRNA Dicerna Pharmaceuticals EIGR Eiger Biopharmaceuticals FATE Fate Therapeutics HARP Harpoon Therapeutics IMRA Imara IPHA Innate Pharma LXRX Lexicon Pharmaceuticals MGNX MacroGenics MRTX Mirati Ther MRUS Merus BV ORIC Oric Pharmaceuticals OVID Ovid Therapeutics PBYI Puma Biotechnology PRQR ProQR Therapeutics BV PTLA Portola Pharmaceuticals RARE Ultragenyx RETA Reata Pharmaceuticals RIGL Rigel Pharmaceuticals UBX Unity Biotechnology XLRN Acceleron Pharma ZLAB Zai Lab Ltd ZYME Zymeworks Common Stock APLT Applied Therapeutics CALT Calliditas Therapeutics GRTX Galera Therapeutics RCUS Arcus Biosciences CMRX Chimerix OPT Opthea Ltd SNDX Syndax Pharmaceuticals SYBX Synlogic RAIN Rain Therapeutics NCNA NuCana PLC BMEA Biomea Fusion IDYA Ideaya Biosciences STTK Shattuck Labs RLYP Relypsa BGNE BeiGene Ltd GRCL Gracell Biotechnologies CHRS Coherus BioSciences KRYS Krystal Biotech AVBP ArriVent BioPharma, Common Stock SMMT Summit Therapeutics PLC ARAV Aravive ISEE IVERIC bio OLMA Olema Pharmaceuticals ACAD ACADIA Pharmaceuticals CADL Candel Therapeutics NBIX Neurocrine Biosciences SLDB Solid Biosciences LLC SRPT Sarepta Therapeutics LENZ LENZ Therapeutics AER AerCap Holdings NV AP Ampco-Pittsburgh CAL Caleres DRTS Alpha Tau Medical Ltd EIG Employers Holdings EYPT Eyepoint Pharmaceuticals MACK Merrimack Pharmaceuticals PROK ProKidney Corp. VBLT Vascular Biogenics Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Yigal Nochomovitz (CITI)